Announcement on Approval by the National Medical Products Administration of the Clinical Trial Application for XNW26018 Tablets
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
(688837)"EVOPOINT BIOSCIENCES CO., LTD."Announcement on Approval by the National Medical Products Administration of the Clinical Trial Application for XNW26018 Tablets
Filed with SSE · Stock code 688837 ·
6ix is reading this filing.
View original source (Shanghai Stock Exchange)Evopoint Biosciences Co Ltd on 6ix
Story so far
- (688837)"EVOPOINT BIOSCIENCES CO., LTD."Announcement on Opening of Dedicated Settlement Accounts for Cash Management Products Purchased with Raised Funds
- Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026
- Announcement on Opening of Dedicated Settlement Accounts for Cash Management Products Purchased with Raised Funds
Earlier from Evopoint Biosciences
- (688837)"EVOPOINT BIOSCIENCES CO., LTD."Announcement on Opening of Dedicated Settlement Accounts for Cash Management Products Purchased with Raised Funds
- Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026
- Announcement on Resolutions of the 17th Meeting of the 2nd Board of Directors
Follow Evopoint Biosciences into a list and get an email when it puts out news.
Follow Evopoint Biosciences